Liquidia Corporation will pay Pharmosa $3.5 million up front plus as much as $157.75 million in milestone payments to extend their existing agreement related to L606 inhaled liposomal treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The deal also includes a license … [Read more...] about Liquidia acquires additional rights to Pharmosa’s liposomal treprostinil inhalation suspension
Business
InCarda says development of FlecIH-103 flecainide inhalation solution will continue despite early termination of Phase 3 trial
According to InCarda, data from the Phase 3 RESTORE-1 trial of FlecIH-103 flecainide inhalation solution for aroxysmal atrial fibrillation (PAF), which was initiated in July 2022, support continued development despite the early termination of the study due to disappointing efficacy and plasma concentrations. InCarda cites delivery problems with the jet nebulizer used … [Read more...] about InCarda says development of FlecIH-103 flecainide inhalation solution will continue despite early termination of Phase 3 trial
ARS launches Neffy nasal epinephrine nasal spray in the US
ARS Pharmaceuticals has launched Neffy epinephrine nasal spray in the US, the company said. In Auguest 2024, Neffy was approved by the FDA for the treatment of anaphylaxis in patients who weigh 30 kg or more. Earlier this month, ARS submitted an sNDA for a lower dose of Neffy for the treatment of anaphylaxis in children weighing 15 to 30 kg (33-66 lbs). European … [Read more...] about ARS launches Neffy nasal epinephrine nasal spray in the US
Fagron gets rights to use PureIMS’s Cyclops DPI with compounded inhalation powders in the Netherlands
PureIMS has announced that personalized medicine company Fagron has acquired exclusive rights to distribute PureIMS's Cyclops dry powder inhaler with compounded inhalation powders in the Netherlands. The Cyclops DPIs, which are pre-filled with drug, will be dispensed by compounding pharmacy Infinity Pharma. According to the announcement, the deal includes … [Read more...] about Fagron gets rights to use PureIMS’s Cyclops DPI with compounded inhalation powders in the Netherlands
Tiziana announces $4 million NIH grant for study of intranasal foralumab for Alzheimer’s disease
Tiziana Life Sciences announced that a study of the company's intranasal anti-CD3 mAb will be funded by a $4 million grant from the National Institutes of Health. In June 2024, the company said that the FDA had approved the use of intranasal foralumab in a patient with moderate Alzheimer’s disease under an expanded access IND. Tiziana said that it anticipates … [Read more...] about Tiziana announces $4 million NIH grant for study of intranasal foralumab for Alzheimer’s disease
Pulmotect raises $5.9 million in Series C funding to support Phase 2 trial of PUL-042 inhalation solution in cancer patients
Pulmotect announced that it has raised $5.9 million in a Series C funding to support a Phase 2 trial of the company's PUL-042 immunostimulant inhalation solution. According to Pulmotect, the new funds will be used along with an $8.9 million Product Development Research grant awarded last year by the Cancer Prevention and Research Institute of Texas (CPRIT) for the … [Read more...] about Pulmotect raises $5.9 million in Series C funding to support Phase 2 trial of PUL-042 inhalation solution in cancer patients
Vectura to be acquired by Phillips Medisize parent Molex
Inhalation CDMO Vectura has been sold to Molex for £150 million up front and up to an additional £148 million in potential payments, the companies have announced. Following the acquisition, Vectura will be operated by Phillips Medisize, which was acquired by Molex in 2016. The sale is expected to close by the end of this year. According to the Vectura Fertin press … [Read more...] about Vectura to be acquired by Phillips Medisize parent Molex
Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Altamira Therapeutics has announced an extension of its 2022 license and distribution agreement that gave Nuance Pharma the rights to market Altamira's Bentrio nasal spray in China, Hong Kong, Macau and South Korea. According to Altamira, Nuance has recently submitted a marketing application for Bentrio in China. The revised deal adds Singapore, Malaysia, Thailand, … [Read more...] about Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
Roivant has revealed that its Pulmovant subsidiary is developing inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), and Pulmovant presented a poster with data from the Phase 1b ATMOS study of mosliciguat at the 2024 ERS Congress. Roivant says that it paid approximately $14 million up front … [Read more...] about Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral
ENA Respiratory announced that it has received a contract extension from the US Department of Defense (DoD), providing additional funds for continued development of INNA-051, a dry powder intranasal TLR2/6 agonist. In January 2023, ENA Respiratory announced that the DoD had provided funding to develop a dry powder formulation of the antiviral, which had previously … [Read more...] about ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral